Market Overview - On June 6, A-shares showed mixed performance with the Shanghai Composite Index rising by 0.04% while the Shenzhen Component Index and the ChiNext Index fell by 0.19% and 0.45% respectively, with approximately 2,600 stocks in the market gaining [1] - The total trading volume in the Shanghai and Shenzhen markets was 11,520.19 billion RMB, indicating a decrease compared to the previous trading day [2] Sector Performance - The non-ferrous metals sector led the gains with an increase of 1.16%, followed by telecommunications at 1.00% and oil and petrochemicals at 0.88%. Conversely, the beauty and personal care sector saw a decline of 1.70%, textiles and apparel fell by 1.18%, and food and beverage dropped by 0.92% [7] Investment Highlights Semiconductor Sector - The semiconductor sector is experiencing significant interest due to the merger of two leading computing companies, which has sparked investment in semiconductor ETFs. The semiconductor ETF (159813) saw a net subscription of over 250 million units on June 6 [8] - The long-term growth potential of the semiconductor industry is highlighted by the increasing demand for AI-driven computing chips and the trend towards domestic substitution in China, benefiting areas such as IP licensing and advanced packaging [8] Pharmaceutical Sector - The ASCO annual meeting showcased numerous innovative research outcomes from local Chinese companies, particularly in the fields of PD-1 monoclonal antibodies and ADCs, with over 70 original research presentations from Chinese researchers [9] - The Chinese innovative drug sector is entering a period of explosive growth in licensing agreements, driven by improved R&D capabilities and increased trust from international pharmaceutical companies [9]

Group 1 - The Hong Kong stock market experienced a decline, with the Hang Seng Index down by 0.31% and the Hang Seng Tech Index down by 0.75%, while the pharmaceutical and biotechnology sector underwent a correction [1] - The Hong Kong Innovative Drug ETF (159567) fell by 0.43%, with a turnover rate exceeding 6% and trading volume quickly surpassing 100 million yuan, indicating active trading [1] - The number of license-out transactions by Chinese pharmaceutical companies reached 33 in Q1 2025, totaling 36.633 billion USD, representing a year-on-year increase of approximately 258%, indicating a shift towards international innovation and research [1] Group 2 - Longcheng Securities suggests that favorable policies for the pharmaceutical sector are emerging, with expectations for steady recovery in industry sentiment, particularly in the hospital market affected by previous anti-corruption and centralized procurement measures [2] - Oriental Securities highlights significant breakthroughs for foreign innovative drugs at the recent ASCO conference, while also noting the strong competitive edge of domestic innovative drugs, recommending attention to companies with international competitive advantages [2]